Fulcrum Therapeutics Inc
NASDAQ:FULC
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Fulcrum Therapeutics Inc
Retained Earnings
Fulcrum Therapeutics Inc
Retained Earnings Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Retained Earnings | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Fulcrum Therapeutics Inc
NASDAQ:FULC
|
Retained Earnings
-$594.3m
|
CAGR 3-Years
-13%
|
CAGR 5-Years
-22%
|
CAGR 10-Years
N/A
|
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Retained Earnings
$169B
|
CAGR 3-Years
11%
|
CAGR 5-Years
8%
|
CAGR 10-Years
5%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Retained Earnings
$16.9B
|
CAGR 3-Years
-13%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
-6%
|
|
|
|
Pfizer Inc
NYSE:PFE
|
Retained Earnings
$114.6B
|
CAGR 3-Years
-3%
|
CAGR 5-Years
3%
|
CAGR 10-Years
5%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Retained Earnings
$73.1B
|
CAGR 3-Years
6%
|
CAGR 5-Years
9%
|
CAGR 10-Years
5%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Retained Earnings
$24.5B
|
CAGR 3-Years
35%
|
CAGR 5-Years
26%
|
CAGR 10-Years
4%
|
|
Fulcrum Therapeutics Inc
Glance View
Fulcrum Therapeutics, Inc. is a clinical stage biopharmaceutical company. The company is headquartered in Cambridge, Massachusetts and currently employs 104 full-time employees. The company went IPO on 2019-07-18. The firm focuses on improving the lives of patients with genetically defined rare diseases. The firm has developed a product engine which identifies drug targets which can modulate gene expression to treat the known root cause of gene mis-expression. The firm is also engaged in developing drugs for the treatment for the root cause of muscle disorders, central nervous system disorders and blood disorders. The firm uses its proprietary product engine to identify and validate drug targets and develop product candidates to address diseases caused by the mis-expression of certain genes. Its product candidate includes losmapimod, is a small molecule that is developed for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, is a small molecule designed to bind embryonic ectoderm development (EED).
See Also
What is Fulcrum Therapeutics Inc's Retained Earnings?
Retained Earnings
-594.3m
USD
Based on the financial report for Dec 31, 2025, Fulcrum Therapeutics Inc's Retained Earnings amounts to -594.3m USD.
What is Fulcrum Therapeutics Inc's Retained Earnings growth rate?
Retained Earnings CAGR 5Y
-22%
Over the last year, the Retained Earnings growth was -14%. The average annual Retained Earnings growth rates for Fulcrum Therapeutics Inc have been -13% over the past three years , -22% over the past five years .
